OND re­or­ga­ni­za­tion moves for­ward

The FDA said Thurs­day that the planned re­or­ga­ni­za­tion of its Of­fice of New Drugs (OND) will move for­ward thanks to Con­gres­sion­al ap­proval, in­clud­ing changes to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER